Targeting SLC36A1 for Treatment of Diseases (G206358)

Target Name: SLC36A1

NCBI ID: G206358

SLC36A1

Targeting SLC36A1 for Treatment of Diseases

SLC36A1 (Lysosomal amino acid transporter 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the SLC transporter family, which is responsible for transporting a variety of proteins, including amino acids, across the cell membrane.

SLC36A1 plays a crucial role in the regulation of amino acid homeostasis in the body. It is responsible for transmitting amino acids from the cytoplasm to the lysosome, where they can be involved in various cellular processes, including protein synthesis, DNA replication, and signaling pathways.

SLC36A1 has also been shown to play a role in the development and progression of certain diseases. For example, studies have suggested that SLC36A1 may be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, SLC36A1 has been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases, including heart disease and diabetes.

Due to its involvement in these processes, SLC36A1 has been identified as a potential drug target or biomarker. Researchers are currently working to develop drugs that can specifically target SLC36A1 and modulate its activity to treat various diseases.

One approach to targeting SLC36A1 is to use small molecules, such as drugs that can modulate the activity of SLC36A1. These molecules can be designed to interact with specific residues on SLC36A1, such as the amino acid residues that are responsible for its stability and function.

Another approach to targeting SLC36A1 is to use antibodies that can specifically recognize and label SLC36A1. These antibodies can then be used to either activate or inhibit SLC36A1, depending on the desired effect on the protein.

Once SLC36A1 has been targeted, researchers can study its function and determine how it contributes to the development and progression of various diseases. This can provide valuable insights into the underlying mechanisms of these diseases and inform the development of new treatments.

In conclusion, SLC36A1 is a protein that plays a crucial role in the regulation of amino acid homeostasis and has been implicated in the development and progression of many diseases. As a potential drug target or biomarker, SLC36A1 is a promising target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of SLC36A1 in these processes and to develop effective treatments.

Protein Name: Solute Carrier Family 36 Member 1

Functions: Electrogenic proton/amino acid symporter with selectivity for small apolar L-amino acids, their D-enantiomers and selected amino acid derivatives such as 4-aminobutanoate/GABA (PubMed:12809675, PubMed:12527723, PubMed:19549785). May be involved in the efflux from the lysosomal compartment of neutral amino acids resulting from proteolysis (By similarity). May play a role in specifying sites for exocytosis in neurons (By similarity)

The "SLC36A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC36A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets